From the presentation: "patients with ≥1kg increases in LBM were more likely to demonstrate a ≥10% increase in SCP"
"if they received enobosarm than placebo." "Overall, enobosarm was safe and well tolerated. Enobosarm had an unambiguous effect on muscle that may translate into improvement in physical function and survival in NSCLC patients" LBM is lean body mass and SCP is stair climb power.
guys lets not act stupid here okay? We are all here to make money not to #$%$ learn about some muscle contraction, lab thing. No explanation needed. The buttom line is are we going to make profits off this company? It annoys me when people make long post explaining the drugs, side effects and trails. Dude some of us dont even NO GTXI is a PHARMA company. WE JUST READING CHARTS and making investments. WE are no scientist. We MAKE MONEY....STOP WITH ALL THE TRIALS EXPlanation #$%$
Credit for the presentation:
P3.11-026 | Results from two Phase 3 randomized trials of enobosarm, selective androgen receptor modulator (SARM), for the prevention and treatment of muscle wasting in NSCLC.
Authors: Jeffrey Crawford1, Carla M.M. Prado2, Michael L. Hancock3, Mary A. Johnston3, James T. Dalton3, Mitchell S. Steiner3 1Duke University School of Medicine, Durham, NC/UNITED STATES OF AMERICA, 2Florida State University, Tallahassee, FL/UNITED STATES OF AMERICA, 3GTx, Inc., Memphis/UNITED STATES OF AMERICA